Bellevue Group AG Has $220.56 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Bellevue Group AG lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 676,367 shares of the biopharmaceutical company’s stock after selling 91,780 shares during the period. Alnylam Pharmaceuticals comprises 4.9% of Bellevue Group AG’s portfolio, making the stock its 4th largest holding. Bellevue Group AG’s holdings in Alnylam Pharmaceuticals were worth $220,557,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. California State Teachers Retirement System increased its stake in Alnylam Pharmaceuticals by 0.9% in the second quarter. California State Teachers Retirement System now owns 199,316 shares of the biopharmaceutical company’s stock valued at $64,995,000 after acquiring an additional 1,873 shares during the period. Quantinno Capital Management LP boosted its holdings in Alnylam Pharmaceuticals by 109.3% during the second quarter. Quantinno Capital Management LP now owns 13,464 shares of the biopharmaceutical company’s stock valued at $4,391,000 after purchasing an additional 7,032 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Alnylam Pharmaceuticals by 49.7% during the second quarter. Alliancebernstein L.P. now owns 67,131 shares of the biopharmaceutical company’s stock valued at $21,891,000 after purchasing an additional 22,294 shares in the last quarter. Nebula Research & Development LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $293,000. Finally, Frontier Capital Management Co. LLC raised its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 103,003 shares of the biopharmaceutical company’s stock worth $33,588,000 after buying an additional 583 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $489.00 price target (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Barclays lifted their price objective on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Evercore ISI boosted their target price on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research note on Thursday, September 11th. JPMorgan Chase & Co. dropped their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $482.71.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,328 shares of company stock valued at $27,288,993 over the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.7%

Shares of NASDAQ:ALNY opened at $397.55 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The firm has a market cap of $52.52 billion, a P/E ratio of 1,656.46 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company’s 50-day moving average price is $452.35 and its two-hundred day moving average price is $406.45.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.